The Zollinger-Ellison syndrome : a case report by Du Toit, D. F. et al.
SAMT DEEL 68 12 OKTOBER 1985 607
The Zollinger-Ellison syndrome
A case report
D. F. DU TOIT, H. LOUWRENS, N. ESTERHUIZEN, V. C. FALCK, L. B. DU TOIT
Summary
A vagotomy and antrectomy was performed on a 15-
year-old 'boy with a malignant gastrinoma for emer-
gency control of massive upper gastro-intestinal
haemorrhage from a large posterior penetrating
duodenal ulcer in the presence of jejunal ulceration
and liver metastases. Hypergastrinaemia was con-
firmed by elevated serum gastrin levels. In the short
term postoperatively the patienfs disease has been
controlled with oral cimetidine. Although controversy
continues over the efficacy of cimetidine in the
management of gastrinomas, medical treatment
should be considered as an alternative to total
gastrectomy in chirdren with malignant gastrinomas
~ because they are often stow-growing, indolent and
compatible with long survival.
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In 1955 Zollinger and Ellison1 described the aSSOClatlon of
pancreatic islet cell lesions, gastric hypersecretion and peptic
ulceration. Marks el al. 2 from Groote Schuur Hospital, Cape
Town, reported 23 years ago on one of the earliest confirmed
cases in South Africa. The Zollinger-Ellison syndrome (ZES)
affects only about one per million individuals but presents
formidable problems in clinical management.3
The medical options and the changing role of surgery in the
management of patients with gastrinoma are discussed.
Case report
A 15-year-old boy was admitted to Tygerberg Hospital with a
short history of severe upper gastro-intestinal haemorrhage,
diarrhoea and weight loss.
The boy was emaciated and anaemic with signs of hypo-
volaemic shock due to severe blood loss. After a period of
resuscitation the patient was subjected to 'urgent operation
after gastroscopic examination had confirmed the presence of a
duodenal ulcer. At laparotomy, an actively bleeding 2 x 2 cm
posterior penetrating duodenal ulcer was observed. Truncal
vagotomy, antrectomy and Billroth 11 gastrectomy were per-
formed.
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A second laparotomy performed 4 days later for intestinal
obstruction confirmed the presence of four jejunal ulcers and a
jejunojejunal intussusception. The intussusception was
manually reduced without need for resection and the non-
perforated jejunal ulcers were oversewn. Histological examina-
tion of hepatic metastases confirmed the clinical suspicion of
malignant gastrinoma (Fig. I). An obvious primary tumour in
the pancreas or duodenal wall could not be identified at
operation or later by ultrasonographic or computed tomo-
graphic (CT) investigation.
Fig. 1. Photomicrograph showing gastrinoma metastases in the
liver (H and E 200).
Postoperatively the patient received total parenteral nutrition
to improve his poor nutritional state, together with intravenous
cimetidine 200 mg 6-hourly. In the short term there were no
untoward side-effects of the treatment. Pre-operative estima-
tion of serum gastrin confirmed that levels were significantly
elevated. There were no biochemical or clinical signs of the
multiple endocrine neoplasm type I (MEN-I) syndrome. Serum
calcium values and radiography and CT of the pituitary fossa
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were within normal limits. The patient made an uneventful
recovery after a stormy postoperative phase and is at present
being maintained on oral cimetidine 200 mg 6-hourly. The
combination of duodenal ulceration, diarrhoea, hyper-
gastrinaemia and histological evidence of hepatic metastases
confirmed the presence of ZES.
Discussion
The ZES is characterized by gastric hypersecretion resulting
in fulminant, intractable, ulcerogenic diathesis, hypergas-
trinaemia and an underlying non-B-cell tumour of the pan-
creas.' Haemorrhage, perforation and obstruction are common
complications. The majority of gastrinomas are situated in the
pancreas and about 13% in the duodenum.' At the time of
diagnosis 60% are malignant, two-thirds having metastasized
at the initial exploration,' and about one-third of patients have
other endocrine tumours - MEN-I syndrome. Apart from
hypergastrinaemia and excessive gastric acid secretion, tumour
localization may be possible by angiography, ultrasound exami-
nation, eT and percutaneous transhepatic pancreatic venous
sampling for gastrin. In patients with borderline or low serum
gastrin levels the calcium and secretin provocative tests have
proved helpful in diagnosing gastrinoma.5,6
In the pre-cimetidine era total gastrectomy was the treat-
ment of choice in most patients regardless of age after clinical
and laboratory confirmation of ZES. The operation was per-
formed even in the presence of extensive regional, lymphatic
or hepatic involvement and resulted in improved quality of
palliation in most patients, notwithstanding advanced
disease. 7- 9
The place of chemotherapy as an adjunct to surgery has
been controversial but some patients with advanced ZES have
responded to streptozotocin alone or in combination with 5-
fluoro-uracil. 9 Total gastrectomy alone gives excellent results,
nutrition rarely being a problem even in children.7•8 Although
about 50% of gastrinomas are malignant they tend to remain
dormant after total gastrectomy, most patients leading a rela-
tively normal life in the absence of weight loss and dumping. 8
Unfortunately, in only a small proportion of cases can the
primary tumour be resected with permanent cure:8•9 However,
some authors have shown that total gastrectomy has been
associated with an appreciable mortality and morbidity. They
point out that almost all totally gastrectomized patients expe-
rience one or several side-effects including oesophageal reflux
symptoms, early satiety and stenosis of the oesophagogastric
junction. Often, these side-effects have been tolerable, but in
some the quality of life has been adversely affected.3
The advent of H 2-receptor antagonists, and their recognized
efficacy in controlling gastric acid hypersecretion, has reopened
the debate on the treatment of ZES. Some workersJ·I(H have
suggested that long-term therapy with H2-receptor antagonists
is preferable to total gastrectomy, which is not free of compli-
cations, and that satisfactory control with cimetidine can be
achieved in most patients. Guidelines for the medical manage-
ment of ZES include administration of cimetidine 300 - 600
mg 4 times daily or ranitidine 300 - 450 mg 4 times daily with
dose adjustment to ensure gastric acid secretion of < 10
mEq/h for the 2-hour period preceding the next dose of
cimetidine.J·lo-15 Published results 14 have indicated that the
presence or absence of symptoms does not reflect the adequacy
of antisecretory control and stress the importance of periodic
gastric analysis. Periodic endoscopy is also essential in eva-
luating the effectiveness of the medical regimen. ll
Disadvantages of treatment include the prohibitive costs of
long-term treatment; clinical failure in 25 - 50% of cases;
development of resistance and cimetidine; side-effects such as
gynaecomastia, impotence, and interference with hepatic detoxi-
fication; the pitfalls of compliance; and life-long commitment
to a rigid schedule of pill_taking.J,IO-15 In addition, the risks
and untoward effects of long-term administration of cimetidine
in very high doses are unknown.
The new H2-receptor blocking agent, ranitidine, or a combi-
nation of anticholinergic drugs and vagotomy may prove useful
alternatives/ ID-15 while the combination of highly selective
vagotomy with pharmacological acid inhibition may also offer
an acceptable alternative in long-term management. 12 The
rationale for this treatment is that the addition of vagotomy
may reduce the requirements of cimetidine, although this
recommendation remains controversial. Malagelada er al. 10 do
not recommend this treatment because their patients with
ZES and previous vagotomy and gastric resection required
doses of cimetidine for symptomatic control similar to those
required by patients who did not undergo vagotomy.
In those patients who develop unacceptable side-effects
because of drug therapy, or wl).ose ulcer diathesis is not
controlled by medical means, the treatment of choice remains
total gastrectomy. In the case under discussion, surgery will
only be implemented should cimetidine fail to control recurrent
haemorrhage and shock.
Addendum
The occurrence of a large stomal ulcer 9 months after Billroth
II gastrectomy and continuous cimetidine treatment necessi-
tated a total gastrectomy. Regression of the liver metastases
was evident. The patient made an excellent recovery.
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